Vividion Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Vividion Therapeutics's estimated annual revenue is currently $72.3M per year.
- Vividion Therapeutics's estimated revenue per employee is $217,000
- Vividion Therapeutics's total funding is $379M.
Employee Data
- Vividion Therapeutics has 333 Employees.
- Vividion Therapeutics grew their employee count by 16% last year.
Vividion Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | President and CEO | Reveal Email/Phone |
2 | VP, Head Early Discovery Chemistry | Reveal Email/Phone |
3 | VP, Functional Genomics | Reveal Email/Phone |
4 | VP, Clinical Immunology | Reveal Email/Phone |
5 | VP, Legal Affairs | Reveal Email/Phone |
6 | SVP Project Management, Project Leadership and Business Operations | Reveal Email/Phone |
7 | VP, Head Chemistry | Reveal Email/Phone |
8 | Head Information Technology | Reveal Email/Phone |
9 | VP Finance | Reveal Email/Phone |
10 | VP, Clinical Development | Reveal Email/Phone |
Vividion Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.4M | 70 | -8% | $53M | N/A |
#2 | $32.4M | 167 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.8M | 18 | 13% | N/A | N/A |
#5 | $0.8M | 5 | -50% | N/A | N/A |
#6 | $0.8M | 10 | 0% | N/A | N/A |
#7 | $14M | 90 | -12% | N/A | N/A |
#8 | $0.4M | 336 | 10% | $236.7M | N/A |
#9 | $4.8M | 62 | -74% | $160M | N/A |
#10 | $3.7M | 24 | -8% | N/A | N/A |
What Is Vividion Therapeutics?
Vividion is a next-generation biotechnology company focused on expanding the therapeutic potential of small molecules. Making accessible the broad set of proteins expressed in human cells, the company's cutting-edge platform was spun out of the labs of Vividion's scientific founders, a team of experts in chemical biology and synthetic chemistry from The Scripps Research Institute in La Jolla, CA. Vividion is committed to advancing and applying its pioneering proteome-wide drug discovery to create life-changing therapeutics.
keywords:N/A
$379M
Total Funding
333
Number of Employees
$72.3M
Revenue (est)
16%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Vividion Therapeutics News
... Protagonist Therapeutics, Reistone Biopharma, Roche, Sandoz, Second Genome, Takeda, Teva Pharmaceuticals, Topivert Pharma, and Vividion Therapeutics;...
Thursday - August 5, 2021 Bayer strengthens drug discovery platform through acquisition of Vividion Therapeutics Acquisition strengthens Bayer's drug discovery capabilities with cutting-edge chemoproteomics platform / Vividion's unique approach identifies previously unknown binding pockets in u ...
The Series C round of financing announced Wednesday included so-called crossover investors, firms that invest in both public and private companies. Securing crossover investment is one of the steps companies take as they prepare for an IPO. Preclinical-stage Vividion is developing small molecul ...
Vividion’s Paige Schaffer works in the company’s lab at its prior location. The company’s drug-discovery platform targets “undruggable” proteins. Photo by Jamie Scott Lytle. Vividion Therapeutics — which formed to transform drug development by targeting “undruggable” proteins — has attracted an ...
Other Companies in
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $50M | 333 | 6% | N/A |
#2 | $74.9M | 333 | N/A | N/A |
#3 | $83.6M | 333 | -3% | N/A |
#4 | $41.6M | 333 | 17% | N/A |
#5 | $15M | 333 | 3% | N/A |